Cancer vaccine in combination with down-modulation of regulatory T cells for patients with incurable cancer

Cancer vaccine in combination with down-modulation of regulatory T cells for patients with incurable cancer - SimVac

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003613

Enrollment

Registered

2010-05-14

Start date

2008-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer, Gastric cancer, Esophageal cancer, Colon cancer, Pancreatic cancer, Breast cancer

Interventions

peptide vaccine 0.3mg peptide vaccine 3mg anti-CD25 antibody (+) anti-CD25 antibody (-)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Standard therapy failure, no standard therapy, HLA-A24, Sufficient organ function, Measurable lesion Histologically-defined incurable esophageal, colon, lung, pancreatic, gastric, and breast cancers Age 20-80 PS 0-2 Estimated prognosis >= 3 months WBC>4,000/mm3, <12,000/mm3 NE>2,000/mm3 PLT>100.000/mm3 Hg>10.0g/dl GOT/GPT<Normal range x 2 Bil<1.5mg/dl Creat<1.5mg/dl

Exclusion criteria

Exclusion criteria: Autoimmune disease Uncontrollable complication infection, diabetes, hypertension, ischemic heart disease, cerebral infarction Pregnancy Allergy Interstitial lung disease

Design outcomes

Primary

Measure	Time frame
Tumor response and safety	—

Countries

Japan

Contacts

Public ContactYoshiyuki YAMAGUCHI

Kawasaki Medical School Department of Clinical Oncology

kasco@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026